淋巴水腫治療的全球市場 (2023～2030年):各終端用戶、產品類型、症狀類型、治療類型的規模、佔有率、成長分析、預測

Global Lymphedema Treatment Market Size, Share, Growth Analysis, By End-User, By Product, By Condition Type, By Treatment Type - Industry Forecast 2023-2030

出版日期: 2023年04月22日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

淋巴水腫治療的市場規模，2021年為7億8653萬美元，2022年為8億6014萬美元，從2023年到2030年的預測期間中預計以9.5％的年複合成長率發展，2030年成長到17億3,536萬美元的規模。

乳癌的發生率上升，淋巴水腫的盛行率上升，市場參與企業引進複數的新產品，技術進步的結果對有效率的產品的需求上升等成為促進淋巴水腫治療市場成長的主要原因。

本報告提供全球淋巴水腫治療的市場調查，市場概要，市場的各種影響因素的分析，技術、革新趨勢，市場規模的變化、預測，各種區分、各地區的明細，競爭情形，主要企業簡介等彙整資訊。

市場概要
市場規模
市場動態
促進因素
機會
阻礙因素
課題
主要的市場洞察
技術分析
價格分析
供應鏈分析
價值鏈分析
市場生態系統
IP分析
貿易分析
Start-Ups分析
原料分析
革新矩陣
開發中產品的分析
宏觀經濟指標
主要投資分析
主要成功因素
競爭的程度
市場動態及預測
市場動態
促進因素
機會
阻礙因素
課題
法規情形
波特分析
未來阻礙相關Skyquest的特別洞察
全球淋巴水腫治療市場:各終端用戶
市場概要
醫院
門診病人手術中心
專門診所
其他
全球淋巴水腫治療市場:各產品
市場概要
加壓繃帶
壓力襪
空氣壓迫設備
其他
全球淋巴水腫治療市場:各症狀類型
市場概要
癌症
心血管疾病
發炎性疾病
其他
全球淋巴水腫治療市場:各治療類型
市場概要
壓迫療法
手術
藥物療法
雷射治療
其他
全球淋巴水腫治療市場:各地區
市場概要
北美
美國
加拿大
歐洲
德國
西班牙
法國
英國
其他的歐洲
亞太地區
中國
印度
日本
韓國
其他的亞太地區
南美
巴西
其他的南美
中東、非洲
GCC各國
南非
其他的中東、非洲
競爭情形
主要5家公司的比較
主要企業的地位
主要企業的採用策略
主要成功策略
市場上最近的活動
主要企業的市場佔有率
主要企業簡介
Bio Compression Systems
Tactile Medical
Medi
Lympha Press
Sigvaris
BSN Medical
L&R USA Inc.
Devon Medical Products
3M Health Care
JOBST USA
Thuasne
Wright Therapy Products
BioHorizons IPH, Inc.
Haddenham Healthcare
ArjoHuntleigh
Paul Hartmann
Bioventus
Baxter International Inc.
CircAid Medical Products, Inc.
Essity Aktiebolag

簡介目錄

Product Code: SQSG35G2016

Lymphedema Treatment Market size was valued at USD 786.53 million in 2021 and is poised to grow from USD 860.14 million in 2022 to USD 1735.36 million by 2030, growing at a CAGR of 9.5% in the forecast period (2023-2030).

A condition known as lymphedema is characterised by abnormal swelling of the body brought on by lymphocytosis as a result of lymphatic system failure. The lower extremity is affected 90% of the time, the upper extremity 10%, and the genitalia 1%. The most common cause of lymphedema (filariasis) is an infection brought on by the parasite Wuchereria bancrofti. Lymphedema is among the most dreaded and unlucky side effects of breast cancer treatment. According to a National Centre for Biotechnology Information (NCBI) research, 40 percent of breast cancer patients experienced lymphedema. The primary factors driving the growth of the lymphedema treatment market are the rising incidence of breast cancer, the rising prevalence of lymphedema, the introduction of several new products by prominent market participants, and the rising need for efficient products as a consequence of technological advancements.

The lymph node draining condition known as lymphedema can appear in cancer patients before or after treatment, according to the US Department of Health and Human Services. For instance, it has been noted that it may occur immediately or up to 30 years after breast cancer treatment. Additionally, 80% of patients start showing symptoms 3 years after surgery, with the remaining 20% developing edoema at a rate of 1% every year. Additionally, after the treatment of gynecologic cancer, a sizeable patient population, primarily women, develops lower-limb lymphedema, with vulvar cancer survivors having the highest frequency (37%) and ovarian cancer survivors having the lowest prevalence (7%). Additionally, the incidence of arm lymphedema varied from 8% to 56% two years after surgery. According to the Alliance Z 1071 longitudinal substudy of the American College of Surgeons Oncology Group (ACOSOG), participants in breast cancer trials report a 3-year cumulative incidence of arm edoema and arm heaviness. Cutting edge and very effective cancer treatment options aid in lowering the risk of lymphedema. The major players in the market for cancer therapeutics are working very hard to introduce innovative products as a result.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lymphedema Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

Based on end-user, the market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others. Based on product, the market is segmented into compression bandages, compression stockings, pneumatic compression devices, others. Based on affected area, the market is segmented into Genital, Lower Extremity, Upper Extremity and Others. Based on age group, the market is segmented into adult and geriatric. Based on route of administration, the market is segmented into Oral, Injectable and Others. Based on type, the market is segmented into primary and secondary lymphedema. Based on condition type, the market is segmented into cancer, cardiovascular diseases, inflammatory diseases, and others. Based on treatment type, the market is segmented into Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others. Based on region, the global market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Driver

As cases of breast cancer and lymphedema rise, it is projected that the market for lymphedema treatments would expand. The likelihood of developing cancer is predicted to rise, creating tremendous opportunity for market expansion. Increasing health spending and growing investments in drug discovery research and development have increased the demand for healthcare facilities. The development of novel lymphedema treatment options is also projected to support market expansion throughout the forecasted period.

The market expansion in the upcoming years is projected to be accelerated by technological developments in lymphedema treatment methods. Additionally, the rise of the market is undoubtedly facilitated by the government's favourable programmes and the reimbursement requirements.

Restraint

Despite advances in technology, there is still no permanent treatment for lymphedema, which is anticipated to limit market growth.

The high cost of procedures and treatments is anticipated to restrict market growth.

Market Trends

As more people experience the ailment, the market for lymphedema treatments is anticipated to grow. Additionally, innovative and cutting-edge treatments are being developed at an exponential rate to lower risk throughout treatment as the disease develops further. Increasing healthcare spending is also predicted to spur industry growth and an increase in healthcare innovation. Additionally, pharmaceutical companies are encouraging worldwide business globalisation by introducing cutting-edge medical equipment.